Glofitamab
- Generic Name
- Glofitamab
- Brand Names
- Columvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2229047-91-8
- Unique Ingredient Identifier
- 06P3KLK2J8
- Background
Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.
...
- Indication
Glofitamab is indicated in Canada for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T c...
- Associated Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Associated Therapies
- -
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05896163
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇺🇸The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas, United States
🇺🇸The University of Kansas Clinical Research Center, Fairway, Kansas, United States
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT05861050
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Australasian Leukaemia and Lymphoma Group
- Target Recruit Count
- 42
- Registration Number
- NCT05833763
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Sir Charles Gairdener, Nedlands, Western Australia, Australia
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with High-risk Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jennifer Crombie, MD
- Target Recruit Count
- 41
- Registration Number
- NCT05800366
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 125
- Registration Number
- NCT05798156
- Locations
- 🇦🇹
Uniklinik Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinikum Magdeburg, Magdeburg, Sachsen-Anhalt, Germany
🇩🇪Uniklinikum Düsseldorf, Düsseldorf, Germany
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Reid Merryman, MD
- Target Recruit Count
- 50
- Registration Number
- NCT05783596
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT05533775
- Locations
- 🇧🇷
Hospital Erasto Gaertner, Curitiba, Brazil
🇧🇷GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, Sao Paulo, Brazil
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05364424
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center UCI, Orange, California, United States
🇺🇸Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 53
- Registration Number
- NCT05219513
- Locations
- 🇫🇷
CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang, Lille, France
🇮🇹ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy
🇮🇹Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT04980222
- Locations
- 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.